Washington University School of Medicine in St. Louis (WashU Medicine) has been awarded a significant five-year, $10.8 million grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This funding renewal aims to advance the institution's ongoing research in
In a significant breakthrough, Poolbeg Pharma announced positive pre-clinical study results for their drug POLB 001, presented at the 66th American Society of Hematology (ASH) Annual Meeting. The study focused on the drug's potential to prevent Cytokine Release Syndrome (CRS), a frequently observed
A recent study spearheaded by University of South Florida (USF) Health researchers, in collaboration with TGH Cancer Institute, has unveiled a potential link between ultra-processed foods and an increased risk of colorectal cancer. Researchers highlighted how these foods may contribute to chronic
In early 2023, the FDA's announcement of a shortage of two critical generic platinum chemotherapy drugs, cisplatin and carboplatin, alarmed the medical community. These drugs have been essential in the treatment of various advanced cancers for over 30 years, particularly lung, head and neck,
Advancements in cancer therapy have brought significant hope, especially with immune checkpoint blockades (ICBs), providing a groundbreaking treatment strategy for advanced cancers. Despite this, the effectiveness of ICBs has often been thwarted by therapeutic resistance, which renders
Ovarian cancer represents a significant health concern worldwide, being the eighth most frequently diagnosed cancer and the leading cause of cancer-related mortality among women globally. In 2022 alone, the disease accounted for over 324,000 new cases and 206,839 deaths across the globe. This
